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Background: Dyslipidemia, a major risk factor for cardiovascular disease is a common finding in patients with type
2 diabetes and among women with gestational diabetes. Elevated levels of lipoprotein(a) [Lp(a)] are linked to
increased risk of cardiovascular disease. However, its relationship with insulin resistance, type 2 diabetes and
gestational diabetes is controversial and unproven. Here we aimed to clarify whether Lp(a) levels are associated
with insulin sensitivity in pregnancy.
Methods: Sixty-four women with gestational diabetes and 165 with normal glucose tolerance were enrolled in the
study. Fasting Lp(a) serum levels were measured in all women at 24–28 weeks of gestation.
Results: In pregnancy, there was no significant difference in serum Lp(a) concentrations between the two groups.
Its level did not correlate with markers of insulin resistance (HOMA-IR), insulin sensitivity (HOMA-S%), pancreatic
beta-cell function (HOMA-B%) and insulin sensitivity in dynamic conditions (OGIS). In addition, fasting glucose and
insulin levels and those throughout an oral glucose tolerance test were independent of Lp(a) concentrations in our
study group.
Conclusions: Lp(a) levels in pregnant women do not differ with respect to the presence or absence of gestational
diabetes. Although influenced by some components of the lipid profile, such as triglycerides and HDL-C, insulin
resistance in pregnancy is not affected by Lp(a).
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Lipoprotein(a) [Lp(a)] is a plasma lipoprotein that consists
of an low-density lipoprotein cholesterol (LDL-C) particle
and the glycoprotein apolipoprotein(a) covalently linked
to apolipoprotein B100 of the LDL-C particle [1]. There
are strong genetic and epidemiological data supporting a
causal relationship between elevated Lp(a) concentrations
and the development of atherosclerosis and cardiovascular
disease (CVD) [2-4]. Type 2 diabetes (T2D) and CVD share
common risk factors, including obesity, hyperinsulinemia
and dyslipidemia [5]. Both diseases can also be prevented
or treated more effectively if they are diagnosed early and
there is substantial interest in identifying new risk factors
involved in their development. Lipid abnormalities* Correspondence: alexandra.kautzky-willer@meduniwien.ac.at
4Department of Internal Medicine III, Division of Endocrinology and
Metabolism, Medical University of Vienna, Waehringer Guertel 18-20, Vienna
1090, Austria
Full list of author information is available at the end of the article
© 2013 Todoric et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
waiver (http://creativecommons.org/publicdom
stated.frequently observed in subjects with insulin resistance
and T2D are hypertriglyceridemia, low high-density
lipoprotein cholesterol (HDL-C), and an increased
fraction of small, dense LDL-C particles [6]. However,
previous reports regarding Lp(a) levels and T2D are
conflicting [7]. Decreased Lp(a) levels in response to
hyperinsulinemia [8,9] and a negative relationship between
Lp(a) levels and the incidence of T2D have been reported
previously [10,11]. In contrast, some studies have shown a
strong positive association between T2D and elevated Lp
(a) levels [12,13]. Similar Lp(a) concentrations in subjects
with T2D and healthy controls have been reported in one
study [14]. No studies so far have investigated the associ-
ation between Lp(a) and insulin sensitivity parameters in
gestational diabetes mellitus (GDM).
GDM, defined as glucose intolerance that begins or is
first detected during pregnancy affects 7% of all pregnancies
[15-17]. The majority of patients with GDM have beta- celll Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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atherogenic lipid profile is a common finding during the
second half of pregnancy and the mechanisms under-
lying such alterations of lipid metabolism are not fully
understood [19,20]. However, dyslipidemia during preg-
nancy may also be a pathological finding suggesting the
development of metabolic syndrome. For example, elevated
triglyceride (TG) levels have been reported in women with
GDM [21] and were associated with diagnosis of GDM [22].
Thus, the goal of this study was to analyze the rela-
tionships between Lp(a) levels and parameters of glucose
metabolism and insulin sensitivity in patients with GDM
and healthy control women during pregnancy.
Methods
Study population
Women enrolled in this study were recruited from the
outpatient clinic of the Division of Endocrinology and
Metabolism at the Medical University of Vienna. Two
hundred and twenty nine pregnant women of a similar age
and body mass index (BMI) were recruited via universal
screening for GDM that was performed with a 2 h, 75 g
oral glucose tolerance test (OGTT) between the 24th and
28th weeks of gestation. Sixty- four women were diagnosed
with GDM and 165 had a normal glucose tolerance
(NGT). Most women were Caucasians (95,6%; 60 GDM
and 159 NGT), whereas 1,7% were of African origin
(1 GDM and 3 NGT) and 2,6% were Asian (3 GDM, 3
NGT). None of these women had a history of GDM or
any history of impaired glucose tolerance. Fasting Lp
(a) concentrations were measured in all women. All
participants provided written informed consent, the
study was conducted in accordance with the Declar-
ation of Helsinki (2008) and approved by the ethics
committee of the Medical University of Vienna. GDM
was diagnosed following the recommendations of the
American Diabetes Association [23].
75 g OGTT
A 75-g OGTT was performed after a 12 h overnight fast.
Plasma glucose and insulin concentrations were measured
before and 30, 60, 90, and 120 min after the ingestion of
the glucose solution. Venous blood sera were obtained
by centrifugation and analyzed immediately or frozen
at −80°C until further analysis.
Assays
Lp(a) was quantified using the turbidimetric LPALX assay
(Roche) on a cobas c 701 analyzer (Roche) according to
the recommendation of the manufacturer. The assay was
independent of apolipoprotein(a) isoform size. Hormones,
metabolic and kidney function parameters were measured
via routine tests in a certified laboratory at the Departmentof Laboratory Medicine of the Medical University of
Vienna.
Data analysis
The trapezoidal rule was used to determine the area under
the concentration curve of glucose, insulin and C-peptide
(AUCg, AUCi and AUCcp, respectively) during the OGTT.
The homeostasis model assessment (HOMA) was used
to evaluate insulin resistance (HOMA-IR), insulin sen-
sitivity indexes (HOMA-S%) and steady state beta-cell
function (HOMA-B%). The HOMA Calculator software
v2.2.2 (http://www.dtu.ox.ac.uk/index.php?maindoc=/homa/
index.php) was utilized for these calculations [24]. During
OGTT, dynamic insulin sensitivity was assessed from the
oral glucose insulin sensitivity index (OGIS) [25].
Statistical analyses
Data are presented as mean ± SE. Distributions of con-
tinuous variables were tested for normality using the
Shapiro-Francia test, and, if appropriate, the natural log
transformations of skewed variables were applied in subse-
quent analyses. Relationships between continuous variables
were evaluated using Spearman rank correlation coeffi-
cients. Multiple linear regression models were constructed
to examine factors that were associated with Lp(a) con-
centration. Two-way ANOVA was performed to evaluate
differences between the groups. Statistical analyses were
performed using SPSS software (SPSS 17.0, Chicago, IL).
A P value of <0.05 was considered statistically significant.
Results
Characteristics of the study population are described in
Table 1. As shown, patients with GDM had significantly
higher fasting glucose, insulin, C-peptide, A1C, TG and
HOMA-IR whereas HOMA-S%, the HDL-C and LDL-C
levels were lower than in the control group (GDM vs
NGT; P < 0.001, P = 0.008, P < 0.001, P < 0.001, P = 0.024,
P = 0.002, P = 0.008, P = 0.005 and P = 0.017, respect-
ively). HOMA-B% value was lower in the GDM women,
but the difference to the control group just failed to
reach statistical significance (P = 0.075). Moreover, GDM
patients showed significantly higher levels of glucose at
all time points during the OGTT (Figure 1A). AUCg,
AUCi and AUCcp were significantly increased in women
with GDM compared with healthy controls (GDM vs
NGT; 18.6 ± 0.4 g/dl × 120 min vs 13.9 ± 0.2 g/dl ×
120 min, P < 0.001; 11.6 ± 0.8 U/l × 120 min vs 8.2 ± 0.3
U/l × 120 min, P < 0.001 and 1177.5 ± 55.9 ng/ml ×
120 min vs 940.2 ± 25.9 ng/ml × 120 min, P < 0.001,
respectively). The OGIS showed lower values in patients
with GDM compared with NGT women (470.4 ± 9.7 ml ×
min -1 × m -2 vs 525 ± 3.8 ml × min -1 × m -2, P < 0.001).
The mean of age, BMI, systolic and diastolic blood pres-
sure, C-reactive protein (CRP), total cholesterol, creatinine,
Table 1 Baseline characteristics, metabolic and hormonal
parameters in women with GDM and healthy controls
GDM NGT
P
n = 64 n = 165
Age, years 33.6 (0.7) 32.6 (0.4) 0.228
BMI, kg/m2 28.9 (0.7) 27.2 (0.4) 0.055
Parity 1.3 (0.2) 1.1 (0.1) 0.110
Systolic blood
pressure (mmHg)
112.9 (1.2) 109.9 (0.9) 0.082
Diastolic blood
pressure (mmHg)
70.4 (1.1) 69.7 (0.8) 0.664
Fasting glucose, mg/dl 87.4 (1.4) 78.4 (0.5) < 0.001
Fasting insulin, mU/l 14.3 (0.9) 11.4 (0.5) 0.008
Fasting C-peptide, μg/l 2.5 (0.1) 1.6 (0.1) < 0.001
A1C, % 5.2 (0.1) 4.8 (0.1) < 0.001
HOMA-IR 1.8 (0.1) 1.4 (0.1) 0.002
HOMA-S% 72.4 (7.5) 92.1 (3.8) 0.008
HOMA-B% 151.2 (7.5) 166.7 (4.6) 0.075
Triglycerides, mg/dl 195.3 (8.3) 173.4 (6.5) 0.024
Total cholesterol, mg/dl 246.9 (5.7) 261.5 (3.7) 0.051
HDL cholesterol, mg/dl 68.9 (2.1) 75.7 (1.2) 0.005
LDL cholesterol, mg/dl 133.9 (5.3) 147.8 (2.8) 0.017
CRP, mg/dl 1.2 (0.3) 0.9 (0.6) 0.471
Creatinine, mg/dl 0.60 (0.01) 0.62 (0.01) 0.084
Estradiol, pg/ml 10113.2 (689.6) 11056.8 (447.8) 0.308
Progesterone, ng/ml 76.9 (6.9) 79.2 (3.5) 0.753
Variables are presented as mean ± S.E. The statistical significance of differences
between the study groups was determined by ANOVA. The P values
correspond to the differences between GDM and NGT women. Statistically























































Figure 1 Serum Lp(a) levels in GDM patients and healthy
pregnant women. (A) Serum glucose concentrations during OGTT.
(B) Fasting Lp(a) serum levels in GDM and NGT women. Data are
expressed as mean ± S.E. *, P < 0.001.
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controls.
The mean level of Lp(a) was 40,89 +/− 5,02 mg/dl and
39,47 +/− 3,37 mg/dl in patients with GDM and healthy
women, respectively and there was no statistically signifi-
cant difference in Lp(a) concentrations between the two
groups (Figure 1B). Most of the variables traditionally
linked to T2D including markers of insulin resistance,
fasting insulin, HOMA-B%, HOMA-S% and HOMA-IR
were not associated with the Lp(a) levels (Table 2, Figure 2).
Serum Lp(a) levels showed a significant positive correlation
with LDL-C and were negatively related to estradiol
(Table 2; P = 0.022 and P = 0.019 respectively). After
adjustment for age and BMI, both LDL-C and estradiol
emerged as independent predictors of Lp(a) concentration
in multiple linear regression analyses (t = 2.474, P = 0.014;
t = −2.164, P = 0.032).
Discussion
Previous studies reported conflicting findings regarding Lp
(a) concentrations in patients with T2D and its relationshipwith insulin resistance [7-14]. In addition, there are lim-
ited data currently available on Lp(a) in GDM, which is
considered a pre-diabetic state. In the present study we
demonstrated that at the time of GDM screening in late
pregnancy women with NGT and GDM patients exhibit
no difference in Lp(a) concentration. Furthermore, Lp(a)
did not show any significant correlation with indices of
insulin resistance and beta-cell function.
It has been demonstrated previously that insulin could
lower Lp(a) levels and an inverse relationship between the
incidence of diabetes and Lp(a) has been reported [8,13].
Interestingly, recent data suggested that only extremely
high concentrations of Lp(a), above the threshold level of
46 mg/dl, are associated with less resistance to insulin
Table 2 Correlations of Lp(a) with metabolic and insulin
sensitivity parameters in the whole study group
rs P
BMI −0.075 0.291
Fasting glucose, mg/dl −0.013 0.850
Fasting insulin, mU/l 0.038 0.570
Fasting C-peptide, μg/l 0.047 0.490
A1C, % 0.024 0.720
Triglycerides, mg/dl −0.031 0.654
Total cholesterol, mg/dl 0.073 0.286
HDL cholesterol, mg/dl −0.081 0.230
LDL cholesterol, mg/dl 0.155 0.022
Estradiol, pg/ml −0.162 0.019
Progesterone, ng/ml −0.039 0.566
AUCg, g/dl x 120 min −0.024 0.726
AUCi, U/l x 120 min −0.018 0.794
AUCcp, ng/ml x 120 min −0.013 0.844
HOMA-S% −0.033 0.631
HOMA-B% −0.014 0.843
OGIS, ml x min -1 x m -2 −0.043 0.556
rs, Spearman correlation coefficient.
Statistically significant P values are labeled with bold text.
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during the course of pregnancy [27,28]. In most studies
Lp(a) levels reached the maximum in the third trimester
and after delivery Lp(a) concentrations returned to the
baseline values [29]. Previous reports have shown different
average Lp(a) levels at their peak in the last trimester of
pregnancy. For example, one longitudinal study reported
median peak Lp(a) values of 47,1 mg/dl [30]. Sattar et al.
noted progressive rise in Lp(a) concentration during normal






















Figure 2 Relationship between insulin resistance and Lp(a) in
the whole study group. Scatterplot represents the correlation
between the Lp(a) and insulin resistance parameter HOMA-IR. rs,
Spearman’s correlation coefficient.gestation [31]. In our study subjects Lp(a) levels were just
above the physiological concentrations, but did not reach
the threshold of 46 mg/dl, which may explain the low
correlation with the markers of insulin resistance.
It would be logical to assume that Lp(a), as a well
established risk factor for CVD may be influenced by
or may influence other known risk factors such as
dyslipidemia or glucose intolerance. For example, blood
glucose was correlated with the risk of coronary heart dis-
ease in the Framingham Offspring Study and was found
to be an independent predictor for cardiovascular mortal-
ity [32,33]. However, there was no significant correlation
between Lp(a) and glycemic biomarkers, fasting glucose,
A1C and AUCg in our study group, which is in agreement
with the findings from at least two other studies [34,35].
Small case-studies showed positive correlation between
Lp(a) and HDL-C and a negative correlation between Lp
(a) and TG [36,37]. In contrast, a low correlation between
Lp(a) and lipids has been shown previously in a large
prospective study of Lp(a) concentration and risk of
T2D in initially healthy US women [11]. Similarly, Lp
(a) did not show a significant correlation with other
serum lipids in our study group, although we observed
a significant positive relationship with LDL-C. This
might be explained because LDL-C is included in the
cholesterol contained in Lp(a) particles. The lack of
correlation between Lp(a) and parameters of glycemia
and lipid metabolism is not surprising given that systemic
Lp(a) concentrations are highly genetically determined
and only a few environmental or physiological factors have
been shown to influence serum Lp(a) levels [38].
Consistent with data from others our women with
GDM showed slightly lower levels of LDL-C than women
with NGT [39]. However, in this study LDL-C postpartum
levels were significantly higher in women who had GDM
than in women who had NGT during pregnancy. Circulat-
ing LDL-C levels may influence the atherothrombotic
impact of Lp(a) and this risk appears to be substantially
attenuated among subjects in whom aggressive LDL-C
lowering has occurred [40-44]. Similarly, as LDL-C and
Lp(a) are correlated it could be possible that GDM
blunted levels of Lp(a) during pregnancy. Therefore, fu-
ture studies are needed to clarify the relationship between
Lp(a) and insulin resistance in women with GDM and
NGT postpartum.
Conclusions
In summary, Lp(a) levels in pregnancy seem to be inde-
pendent of the presence or absence of GDM. Additionally,
our data suggest that the pathophysiological mechanisms
of insulin resistance in GDM are not related to the Lp(a)
concentration during pregnancy. Further studies are needed
to explore the relationship between Lp(a) and insulin sensi-
tivity in women with NGTand GDM postpartum.
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